Is it possible to develop pan-arthropod vaccines?
Hematophagous arthropods that transmit the etiological agents of arthropod-borne diseases have become the focus of anti-vector vaccines, targeted mainly at components of their saliva and midgut. These efforts have been directed mostly towards developing species-specific vaccines. An alternative is to target cross-reactive epitopes that have been preserved during evolution of the arthropods. The N- and O-linked glycans that are attached to arthropod glycoproteins are one of the potential targets of this pan-arthropod vaccine approach. Here, we discuss how genetically modified Drosophila melanogaster cells can be used to synthesize and to deliver these arthropod glycans to vertebrate hosts.
Mejia
J Santiago
JS
Department of Microbiology, Immunology and Pathology, Colorado State University, 1619 Campus Delivery, Fort Collins, CO 80523, USA. jsmejia@colostate.edu
Bishop
Jeanette V
JV
Titus
Richard G
RG
D000818:Animals; D001179:Arthropod Vectors / Q000276:immunology*; D001181:Arthropods / Q000276:immunology*; D000939:Epitopes / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology*; D019476:Insect Proteins / Q000276:immunology; D012449:Safety; D012463:Saliva / Q000276:immunology; D014611:Vaccination; D022223:Vaccines, Subunit
D000939:Epitopes; D007155:Immunologic Factors; D019476:Insect Proteins; D022223:Vaccines, Subunit